Cargando…
Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
Secondary myelodysplasia (MDS) and acute myeloid leukemia (AML) are frequent long term complications in Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) patients. Although disease-related immune-suppression plays a crucial role in leukemogenesis there is great concern that t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152453/ https://www.ncbi.nlm.nih.gov/pubmed/21869917 http://dx.doi.org/10.4084/MJHID.2011.031 |
_version_ | 1782209766291931136 |
---|---|
author | Ricci, Francesca Tedeschi, Alessandra Montillo, Marco Morra, Enrica |
author_facet | Ricci, Francesca Tedeschi, Alessandra Montillo, Marco Morra, Enrica |
author_sort | Ricci, Francesca |
collection | PubMed |
description | Secondary myelodysplasia (MDS) and acute myeloid leukemia (AML) are frequent long term complications in Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) patients. Although disease-related immune-suppression plays a crucial role in leukemogenesis there is great concern that therapy may further increase the risk of developing these devastating complications. Nucleoside analogs (NA) and alkylating agents are considered appropriate agents in the treatment of both CLL and WM patients. Prolonged immunosuppression related to NA therapy and the incorporation of these agents or their metabolites into DNA, with potentially mutagenic action, leads to speculation that their therapeutic use might be responsible for an increased incidence of second cancer especially when combined with other DNA damaging agents like alkylating agents. In this review the published studies considering the occurrence of secondary MDS and AML in CLL and WM patients are reported and the potential role of chemotherapeutic agents in leukemogenesis is discussed. |
format | Online Article Text |
id | pubmed-3152453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Università Cattolica del Sacro Cuore |
record_format | MEDLINE/PubMed |
spelling | pubmed-31524532011-08-25 Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia Ricci, Francesca Tedeschi, Alessandra Montillo, Marco Morra, Enrica Mediterr J Hematol Infect Dis Original Articles Secondary myelodysplasia (MDS) and acute myeloid leukemia (AML) are frequent long term complications in Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) patients. Although disease-related immune-suppression plays a crucial role in leukemogenesis there is great concern that therapy may further increase the risk of developing these devastating complications. Nucleoside analogs (NA) and alkylating agents are considered appropriate agents in the treatment of both CLL and WM patients. Prolonged immunosuppression related to NA therapy and the incorporation of these agents or their metabolites into DNA, with potentially mutagenic action, leads to speculation that their therapeutic use might be responsible for an increased incidence of second cancer especially when combined with other DNA damaging agents like alkylating agents. In this review the published studies considering the occurrence of secondary MDS and AML in CLL and WM patients are reported and the potential role of chemotherapeutic agents in leukemogenesis is discussed. Università Cattolica del Sacro Cuore 2011-07-09 /pmc/articles/PMC3152453/ /pubmed/21869917 http://dx.doi.org/10.4084/MJHID.2011.031 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Ricci, Francesca Tedeschi, Alessandra Montillo, Marco Morra, Enrica Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia |
title | Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia |
title_full | Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia |
title_fullStr | Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia |
title_full_unstemmed | Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia |
title_short | Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia |
title_sort | therapy-related myeloid neoplasms in chronic lymphocytic leukemia and waldenstrom’s macroglobulinemia |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152453/ https://www.ncbi.nlm.nih.gov/pubmed/21869917 http://dx.doi.org/10.4084/MJHID.2011.031 |
work_keys_str_mv | AT riccifrancesca therapyrelatedmyeloidneoplasmsinchroniclymphocyticleukemiaandwaldenstromsmacroglobulinemia AT tedeschialessandra therapyrelatedmyeloidneoplasmsinchroniclymphocyticleukemiaandwaldenstromsmacroglobulinemia AT montillomarco therapyrelatedmyeloidneoplasmsinchroniclymphocyticleukemiaandwaldenstromsmacroglobulinemia AT morraenrica therapyrelatedmyeloidneoplasmsinchroniclymphocyticleukemiaandwaldenstromsmacroglobulinemia |